dicloxacillin has been researched along with probenecid in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bommareddy, A; Gionfriddo, MR; Heindel, GA; Mukhija, P; Vanwert, AL; Witkowski, S; Wolman, AT | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Prober, CG; Yeager, AS | 1 |
| Carleton, J; Hamburger, M; Hartman, RE; Lustberg, A | 1 |
| Høiby, N; Szaff, M | 1 |
| Hedström, SA; Kahlmeter, G | 1 |
| Chayakul, P; Yipintsoi, T | 1 |
| Hansen, BA; Jensen, P; Krogsgaard, MR; Slotsbjerg, T | 1 |
| Beringer, PM; Burckart, GJ; Gill, M; Hidayat, L; Kriengkauykiat, J; Liu, S; Louie, S; Rao, PA; Shapiro, B; Synold, T; Zhang, X | 1 |
1 review(s) available for dicloxacillin and probenecid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for dicloxacillin and probenecid
| Article | Year |
|---|---|
Should probenecid be used to reduce the dicloxacillin dosage in orthopaedic infections? A study of the dicloxacillin-saving effect of probenecid.
Topics: Administration, Oral; Biological Availability; Dicloxacillin; Drug Therapy, Combination; Humans; Orthopedics; Postoperative Complications; Probenecid; Staphylococcal Infections | 1994 |
Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Contrast Media; Cyclosporine; Cystic Fibrosis; Dicloxacillin; Drug Interactions; Female; Glomerular Filtration Rate; Humans; Iothalamate Meglumine; Kidney; Male; Organic Anion Transporters; Polymorphism, Genetic; Probenecid; Prospective Studies | 2008 |
15 other study(ies) available for dicloxacillin and probenecid
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Biological Transport; Cell Line, Transformed; Humans; Mice; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Solubility; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Use of the serum bactericidal titer to assess the adequacy of oral antibiotic therapy in the treatment of acute hematogenous osteomyelitis.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Cephalexin; Child; Child, Preschool; Dicloxacillin; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Infant; Injections, Intravenous; Methicillin; Nafcillin; Osteomyelitis; Penicillin V; Probenecid; Protein Binding | 1979 |
Effect of dicloxacillin, oxacillin, and nafcillin upon staphylococcal population and rate of healing of soft-tissue lesions.
Topics: Cloxacillin; Dicloxacillin; Humans; Nafcillin; Oxacillin; Penicillins; Probenecid; Staphylococcal Infections | 1966 |
Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Dicloxacillin; Female; Fusidic Acid; Humans; Infant; Male; Oxacillin; Probenecid; Pseudomonas Infections; Rifampin; Staphylococcal Infections | 1982 |
Dicloxacillin and flucloxacillin twice daily with probenecid in staphylococcal infections. A clinical and pharmakokinetic evaluation.
Topics: Cloxacillin; Dicloxacillin; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Floxacillin; Furunculosis; Humans; Osteomyelitis; Probenecid; Recurrence; Staphylococcal Infections; Staphylococcus aureus; Surgical Wound Infection | 1980 |
Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis.
Topics: Administration, Oral; Adult; Aged; Cloxacillin; Dicloxacillin; Drug Administration Schedule; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Gentamicins; Humans; Infusions, Intravenous; Male; Middle Aged; Probenecid; Staphylococcal Infections; Staphylococcus aureus; Staphylococcus epidermidis | 1993 |